SEC Comment Letter for KIWA BIO-TECH PRODUCTS GROUP CORP (CIK 0001159275) — Mar 23, 2020
KIWA BIO-TECH PRODUCTS GROUP CORP (CIK 0001159275)
Date: March 23, 2020 · CIK: 0001159275 · Accession: 0000000000-20-002524
AI Filing Summary & Sentiment
File numbers found in text: 000-33167
Letter
March 23, 2020 Wade Li Chief Executive Officer Kiwa Bio-Tech Products Group Corporation 3200 Guasti Road, Suite #100 Ontario, California 91761 Re:Kiwa Bio-Tech Products Group Corporation Preliminary Information Statement on Schedule 14C Filed March 18, 2020, as amended File No. 000-33167 Dear Mr. Li: We have reviewed your filing and have the following comment. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Preliminary Information Statement on Schedule 14C filed March 18, 2020, as amended General 1.We note that you have obtained the consent of 75% of shareholders to increase the number of authorized shares of common stock. Please revise your disclosure to state whether you have plans, proposals or arrangements to issue any of the additional shares. In that regard, we note your Form 8-K filed February 13, 2020 regarding the issuance of convertible promissory notes on February 5, 2020. If you have plans to issue the newly authorized shares of common stock in connection with the conversion of promissory notes or any other plans for the issuance of such shares, please provide the information required by Item 11 of Schedule 14A. Refer to Item 1 of Schedule 14C and Note A to Schedule 14A. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
FirstName LastNameWade Li Comapany NameKiwa Bio-Tech Products Group Corporation March 23, 2020 Page 2 FirstName LastName Wade Li Kiwa Bio-Tech Products Group Corporation March 23, 2020 Page 2 Please contact Irene Paik at 202-551-6553 or Celeste Murphy at 202-551-3257 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert L. B. Diener, Esq.
Show Raw Text
March 23, 2020
Wade Li
Chief Executive Officer
Kiwa Bio-Tech Products Group Corporation
3200 Guasti Road, Suite #100
Ontario, California 91761
Re:Kiwa Bio-Tech Products Group Corporation
Preliminary Information Statement on Schedule 14C
Filed March 18, 2020, as amended
File No. 000-33167
Dear Mr. Li:
We have reviewed your filing and have the following comment.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Preliminary Information Statement on Schedule 14C filed March 18, 2020, as amended
General
1.We note that you have obtained the consent of 75% of shareholders to increase the
number of authorized shares of common stock. Please revise your disclosure to state
whether you have plans, proposals or arrangements to issue any of the additional shares.
In that regard, we note your Form 8-K filed February 13, 2020 regarding the issuance of
convertible promissory notes on February 5, 2020. If you have plans to issue the newly
authorized shares of common stock in connection with the conversion of promissory notes
or any other plans for the issuance of such shares, please provide the information required
by Item 11 of Schedule 14A. Refer to Item 1 of Schedule 14C and Note A to Schedule
14A.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
FirstName LastNameWade Li
Comapany NameKiwa Bio-Tech Products Group Corporation
March 23, 2020 Page 2
FirstName LastName
Wade Li
Kiwa Bio-Tech Products Group Corporation
March 23, 2020
Page 2
Please contact Irene Paik at 202-551-6553 or Celeste Murphy at 202-551-3257 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Robert L. B. Diener, Esq.